Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin

被引：0
|
作者：
Gayatri Sathyan
Roger R. Dmochowski
Rodney A. Appell
Cindy Guo
Suneel K. Gupta
机构：
[1] ALZA Corporation,Department of Clinical Pharmacology
[2] Vanderbilt University Medical Center,Department of Urologic Surgery
[3] Baylor College of Medicine,Scott Department of Urology
来源：
Clinical Pharmacokinetics | 2004年 / 43卷
关键词：
Drug Release; Oxybutynin; Tolterodine; Poor Metaboliser; Active Moiety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1059 / 1068
页数：9
相关论文
共 50 条
  • [41] Methylphenidate - An update on extended-release formulations
    Zolezzi, Monica
    NEUROSCIENCES, 2007, 12 (01) : 3 - 7
  • [42] Extended-release formulations for the treatment of epilepsy
    Bialer, Meir
    CNS DRUGS, 2007, 21 (09) : 765 - 774
  • [43] Photostability of extended-release matrix formulations
    Maggi, L
    Machiste, EO
    Fasani, E
    Albini, A
    Segale, L
    Conte, U
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 55 (01) : 99 - 105
  • [44] Cognitive effects of Immediate Release and extended-release oxybutynin in an elderly population
    Sand, Peter K.
    Modi, Nishit B.
    Gupta, Suneel
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 4S - 4S
  • [45] Extended-Release Formulations for the Treatment of Epilepsy
    Meir Bialer
    CNS Drugs, 2007, 21 : 765 - 774
  • [46] Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers
    Zhao, QY
    Janssens, L
    Verhaeghe, T
    Brashear, HR
    Truyen, L
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) : 1547 - 1554
  • [47] Pharmacokinetics, metabolism, and saliva output during transidermal and extended-release oral oxybutynin administration in healthy subjects
    Appell, RA
    Chancellor, MB
    Zobrist, RH
    Thomas, H
    Sanders, SW
    MAYO CLINIC PROCEEDINGS, 2003, 78 (06) : 696 - 702
  • [48] Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study
    Appell, RA
    Sand, P
    Dmochowski, R
    Anderson, R
    Zinner, N
    Lama, D
    Roach, M
    Miklos, J
    Saltzstein, D
    Boone, T
    Staskin, DR
    Albrecht, D
    MAYO CLINIC PROCEEDINGS, 2001, 76 (04) : 358 - 363
  • [49] Management of overactive bladder - Defining the role of extended-release tolterodine
    Keam, SJ
    Perry, CM
    DISEASE MANAGEMENT & HEALTH OUTCOMES, 2004, 12 (02) : 121 - 142
  • [50] Pharmacokinetics and tolerability of extended-release clarithromycin
    Guay, DRP
    Gustavson, LE
    Devcich, KJ
    Zhang, J
    Cao, GL
    Olson, CA
    CLINICAL THERAPEUTICS, 2001, 23 (04) : 566 - 577
12345